Quick answer
Roivant Sciences Ltd. (ROIV) reported revenue of $8.3M and net loss of $299.8M for the fiscal year ended 2026-03-31, down 71.6% from $29.1M the year before, per its 10-K filed with the SEC on 2026-05-20.
Data as of 2026-03-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2026 (FY ending 2026-03-31) | $8.3M | -$299.8M | — |
| 2025 (FY ending 2025-03-31) | $29.1M | -$172.0M | — |
| 2024 (FY ending 2024-03-31) | $32.7M | $4.35B | $430.6M |
| 2023 (FY ending 2023-03-31) | $31.5M | -$1.01B | $375.5M |
| 2022 (FY ending 2022-03-31) | $55.3M | -$845.3M | $210.0M |
| 2021 (FY ending 2021-03-31) | $23.8M | -$809.2M | $170.3M |
Related
- RMBS revenue, net income and debt history (Rambus Inc)
- RMD revenue, net income and debt history (ResMed Inc.)
- RNR revenue, net income and debt history (Renaissancere Holdings Ltd)
- ROK revenue, net income and debt history (Rockwell Automation, Inc.)
- ROKU revenue, net income and debt history (Roku, Inc.)
- ROL revenue, net income and debt history (Rollins, Inc.)
- ROP revenue, net income and debt history (Roper Technologies, Inc.)
- ROST revenue, net income and debt history (Ross Stores, Inc.)
Last updated 2026-10-16. Data only, not financial or tax advice.